Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
about
Plasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells.Ultrasonic-activated micellar drug delivery for cancer treatment.Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiencyEnhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapyEnhanced cytotoxicity for colon 26 cells using doxorubicin-loaded sorbitan monooleate (Span 80) vesiclesNanotechnology of emerging targeting systems.Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles.Multifunctional, stimuli-sensitive nanoparticulate systems for drug deliveryA biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents. [Corrected]HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery.Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection deliverypH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug deliveryTumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.Recent advances in protection against doxorubicin-induced toxicity.Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.Liposomal cancer therapy: exploiting tumor characteristics.The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.Challenges in development of targeted liposomal therapeutics.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsLiposomes in drug delivery: a patent review (2007 - present).Enhanced cytotoxicity of optimized liposomal genistein via specific induction of apoptosis in breast, ovarian and prostate carcinomas.PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells.Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.The new era of nanotechnology, an alternative to change cancer treatment.Targeted delivery of insulin-modified immunoliposomes in vivo.SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.
P2860
Q30458534-1D8054B3-7665-488C-AE21-376A9A933590Q30490995-FFAD3CBF-5318-41F5-87C0-887D8531F50BQ33529963-80FD7854-63E2-459D-8543-FDFA8CD02AC0Q33596415-F36DA245-B53A-4684-BBDF-26A677AD9842Q34089324-D566B6A8-F468-49B6-A619-96C29FC533F2Q34587836-D521D73A-E70A-4875-B7EF-AE6A441B0CEEQ35048646-3CA9FA9E-CD1F-42FA-94CA-908FC731B11EQ35172556-6FBECF80-F7DA-459E-98D5-52A907B47440Q35809872-E91ACC8C-888F-43B5-B5D0-01EEB4757ECCQ35856410-113F2D52-28F3-49CC-9904-2EABA565DA7BQ36046167-684682F1-60C9-4D36-AACB-4675BEF5C93DQ36277841-E9D23D1A-51CC-41CC-BF52-66A070A40FE4Q36653608-09878360-6986-46E9-8314-117DAFDFCF2EQ37117472-B7E3AB53-2057-4B87-9BDD-A7474633359EQ37188366-E305B2F9-C479-4B26-8332-DA979FBA5BEAQ37338134-9D782647-4AAF-4A89-8876-E75F8316829AQ37389006-4445165C-754A-41EA-9875-CF812D3BE953Q37444094-EC88D3E5-BA05-4AF4-8F8F-91086F807035Q37679954-6F00D5BA-7303-4132-A303-95A9DBAD4423Q37815479-353BA1B3-B0F6-4E29-98FD-29DAE863EEC9Q37993466-21D9E934-C2BC-47AE-BBDA-E2E0E3E8D460Q38042256-11BE0562-6C6C-42E5-A063-25D3E60EE8DEQ38129924-5B132A24-72F4-49EE-8846-3BA32E2592B6Q39073033-1AB0E1DE-5005-4CC2-842A-E45FF3148343Q39364129-2856C2C1-4E04-4575-BC7F-027D04CE6472Q39381365-A90FC87E-4624-46EE-B0D2-09F00910C4E3Q39425556-E85C8B73-61D5-4A4E-9519-B56C802F5C61Q39622438-73B7B1F2-2C90-4B65-9073-A886FD30D522Q39953099-4B3E8C74-2328-412C-A6E1-3E8B7987453AQ42370576-63138B10-3171-4B44-853B-FB8C5C670F41Q46113442-4BDD365B-44AB-40C7-A733-CE4D3550487AQ55379526-03D81E01-D226-47F2-B583-E17BAE467BE0
P2860
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Enhanced cytotoxicity of monoc ...... inst various tumor cell lines.
@ast
Enhanced cytotoxicity of monoc ...... inst various tumor cell lines.
@en
type
label
Enhanced cytotoxicity of monoc ...... inst various tumor cell lines.
@ast
Enhanced cytotoxicity of monoc ...... inst various tumor cell lines.
@en
prefLabel
Enhanced cytotoxicity of monoc ...... inst various tumor cell lines.
@ast
Enhanced cytotoxicity of monoc ...... inst various tumor cell lines.
@en
P2860
P1476
Enhanced cytotoxicity of monoc ...... inst various tumor cell lines.
@en
P2093
Tamer A Elbayoumi
Vladimir P Torchilin
P2860
P304
P356
10.1016/J.EJPS.2007.05.113
P407
P577
2007-06-07T00:00:00Z